Patrick O'Brien compensation by year
ARROWHEAD PHARMACEUTICALS Summary Compensation Table · all 7 fiscal years held| Component | FY2016 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $375,949 | $459,100 | $479,762 | $500,466 | $568,422 | $605,259 | $653,940 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Stock awards | $0 | $4,440,100 | $4,603,800 | $3,978,000 | $2,475,200 | $2,935,050 | $1,979,000 |
| Option awards | $276,575 | $0 | $0 | $0 | $0 | $0 | $0 |
| Non-equity incentive | $170,820 | $211,500 | $239,630 | $235,599 | $252,000 | $378,000 | $365,638 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $11,399 | $12,802 | $13,734 | $13,798 | $14,715 | $15,261 | $31,617 |
| Total | $834,743 | $5,123,502 | $5,336,926 | $4,727,863 | $3,310,337 | $3,933,570 | $3,030,195 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ARROWHEAD PHARMACEUTICALS, INC. DEF 14A filed January 27, 2026, accession 0000879407-26-000019, and prior-year filings.
How this page was built: the ARROWHEAD PHARMACEUTICALS, INC. filed document, accession 0000879407-26-000019. Every figure is read from that document and cited to the page and table it appears in. Filed January 27, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 100,000 | $3,449,000 | — |
| RSU | 63,750 | $2,198,738 | — |
| RSU | 32,500 | $1,120,925 | — |
| RSU | 15,000 | $517,350 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in ARROWHEAD PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments ARROWHEAD PHARMACEUTICALS discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $325,000 | $0 | $49,069 | $374,069 |
| Change in control, no termination | $0 | $7,286,013 | $0 | $7,286,013 |
| Change in control and involuntary termination | $650,000 | $7,286,013 | $73,604 | $8,448,367 |
Per the Potential Payments Upon Termination or Change in Control table in ARROWHEAD PHARMACEUTICALS, INC.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
ARROWHEAD PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Christopher Anzalone | President and Chief Executive Officer | $9,029,861 |
| Patrick O'Brien · this page | Chief Operating Officer | $3,030,195 |
| James Hamilton | Chief Medical Officer | $2,966,213 |
| Kenneth Myszkowski | Former Chief Financial Officer | $2,660,161 |
| Daniel Apel | Chief Financial Officer | $1,754,912 |
| Tracie Oliver | Former Chief Commercial Officer | $43,193 |
Patrick O'Brien's compensation dossier, ARROWHEAD PHARMACEUTICALS
You have read Patrick O'Brien's totals and holdings. The dossier adds each equity grant ARROWHEAD PHARMACEUTICALS disclosed for Patrick O'Brien and ARROWHEAD PHARMACEUTICALS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full ARROWHEAD PHARMACEUTICALS compensation record
free company briefThis page is one person within ARROWHEAD PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ARROWHEAD PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ARROWHEAD PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ARROWHEAD PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.